<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/shutterstock_1957130641-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/shutterstock_1957130641-430x241.jpg"/></p>
<p>三个目标产品概况（TPPs）包括关于新治疗方法开发的具体指导，为创新提供了一个发展框架。来源：Prrrettty/Shutterstock.com。</p>
<p>世界卫生组织（WHO）已概述了针对三种优先感染的期望抗菌特性，作为引导研究开发急需抗生素的一部分。</p>
<p>WHO 发布的三个目标产品概况（TPPs）包括关于新治疗方法开发的具体指导，为创新提供了一个发展框架。这些新的 TPPs 与该机构的细菌优先病原体名单一致，旨在促进公共和私营部门合作伙伴之间的合作，以激励并降低与重大医疗负担感染的研究和开发相关的风险。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - BWC-0977 在阿克曼菌感染中的应用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - BWC-0977 在炭疽杆菌感染中的应用</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>世界卫生组织将严重多重耐药（MDR）阴性革兰氏菌感染、免疫抑制和危重病患者的严重阳性革兰氏菌感染以及细菌性脑膜炎列为三项全球创新优先事项。开发更好的抗生素将有助于解决全球高风险人群中的严重血流感染和尿路感染、肺炎和中枢神经系统炎症。细菌性脑膜炎尤其危险——受影响者中大约每六人就有一人死亡。</p>
<p>尽管根据 WHO 的抗菌素 2025 报告，约有 90 种新的抗菌剂正在进行临床前或临床开发，但很少有临床候选药物针对细菌优先病原体。该机构认为，甚至更少的药物被视为 “创新”。</p>
<p>WHO 抗微生物耐药性主任 Yvan Hutin 博士表示：“科学界近年来开发并批准了新的抗生素。这是好事，但不幸的是，无法赶上不断演变的耐药细菌，尤其是那些最令人担忧的细菌。”</p>
<p>“我们需要一个可靠的管道，提供创新、可负担且所有需要的人都能获得的新抗菌剂。”</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预测？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>来自 GlobalData</p>
<p>了解更多关于战略情报</p>
<h2>抗微生物耐药性（AMR）的健康负担</h2>
<p>抗微生物耐药性（AMR）是指细菌、病毒、真菌和寄生虫进化以抵抗抗微生物药物。在耐药细菌的情况下，抗生素可能失效。2023 年，全球约六分之一的实验室确认的细菌感染是由耐药细菌引起的。估计 2019 年，细菌抗微生物耐药性（AMR）直接导致了 127 万人死亡，这是最后一年有此类数据可用的年份。预计如果不采取行动，例如开发更先进的抗生素，到 2050 年 AMR 将导致 1000 万人死亡。</p>
<p>2025 年 10 月，WHO 要求其成员国、捐助者和合作伙伴加强对抗 AMR 的协调响应。当时，卫生机构要求每两年提供 8500 万美元以帮助应对这一公共卫生问题。目前尚不清楚 美国退出 WHO 将如何具体影响 AMR，但专家普遍认为，该机构的全球健康努力将受到阻碍。美国历来是 WHO 最大的捐助国。</p>
<p>其他地区已建立自己的运动。例如，英国 承诺 210 百万英镑（约 267.7 百万美元） 以帮助追踪亚洲和非洲的抗生素耐药细菌。这项投资支持弗莱明基金的全球抗微生物耐药性监测（AMR）计划，旨在在危险超级细菌到达英国之前识别它们。2025 年 9 月，欧盟启动了一项 2.53 亿欧元的倡议，以应对 AMR。</p>

<p>世界卫生组织（WHO）发布了三种优先感染的目标产品轮廓（TPPs），以指导急需抗生素的开发。这些 TPPs 旨在促进公共和私营部门之间的合作，以应对严重的多重耐药感染和细菌性脑膜炎。尽管目前有 90 种新的抗菌药物在开发中，但很少有针对优先病原体。WHO 强调需要创新且价格合理的抗生素来对抗抗微生物耐药性（AMR），该问题在 2019 年导致了 127 万人死亡，预计如果不采取行动，到 2050 年将导致 1000 万人死亡</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/shutterstock_1957130641-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/shutterstock_1957130641-430x241.jpg"/></p>
<p>The three Target Product Profiles (TPPs) include specific guidance on the development of new treatments, providing a developmental framework to align innovation. Credit: Prrrettty/Shutterstock.com.</p>
<div class="lb-trans"><p>三个目标产品概况（TPPs）包括关于新治疗方法开发的具体指导，为创新提供了一个发展框架。来源：Prrrettty/Shutterstock.com。</p>
</div><p>The World Health Organization (WHO) has outlined desired antibacterial characteristics for three priority infections as part of a move to direct research towards developing urgently needed antibiotics.</p>
<div class="lb-trans"><p>世界卫生组织（WHO）已概述了针对三种优先感染的期望抗菌特性，作为引导研究开发急需抗生素的一部分。</p>
</div><p>The three Target Product Profiles (TPPs) published by WHO include specific guidance on the development of new treatments, providing a developmental framework to align innovation. The new TPPs are in line with the agency’s bacterial priority pathogen list, aiming to foster collaboration between public and private sector partners to incentivise and reduce the risks associated with research and development for infections with significant healthcare burden.</p>
<div class="lb-trans"><p>WHO 发布的三个目标产品概况（TPPs）包括关于新治疗方法开发的具体指导，为创新提供了一个发展框架。这些新的 TPPs 与该机构的细菌优先病原体名单一致，旨在促进公共和私营部门合作伙伴之间的合作，以激励并降低与重大医疗负担感染的研究和开发相关的风险。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - BWC-0977 in Acinetobacter Infections</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - BWC-0977 在阿克曼菌感染中的应用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - BWC-0977 in Bacillus anthracis Infections</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - BWC-0977 在炭疽杆菌感染中的应用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>Severe multidrug-resistant (MDR) gram-negative infections, severe gram-positive infections in immunosuppressed and critically ill patients, and bacterial meningitis have been picked by WHO as three global priorities for innovation. Developing better antibiotics for these would help address severe bloodstream and urinary tract infections, pneumonia and central nervous system inflammations in at-risk populations worldwide. Bacterial meningitis remains particularly dangerous – of those affected, approximately one person in six dies.</p>
<div class="lb-trans"><p>世界卫生组织将严重多重耐药（MDR）阴性革兰氏菌感染、免疫抑制和危重病患者的严重阳性革兰氏菌感染以及细菌性脑膜炎列为三项全球创新优先事项。开发更好的抗生素将有助于解决全球高风险人群中的严重血流感染和尿路感染、肺炎和中枢神经系统炎症。细菌性脑膜炎尤其危险——受影响者中大约每六人就有一人死亡。</p>
</div><p>Despite 90 new antibacterial agents being in preclinical or clinical development across various infections, as per the WHO’s antibacterial 2025 report, few clinical candidates target bacterial priority pathogens. The agency considers even a smaller amount as ‘innovative’.</p>
<div class="lb-trans"><p>尽管根据 WHO 的抗菌素 2025 报告，约有 90 种新的抗菌剂正在进行临床前或临床开发，但很少有临床候选药物针对细菌优先病原体。该机构认为，甚至更少的药物被视为 “创新”。</p>
</div><p>Dr Yvan Hutin, director of antimicrobial resistance at WHO, said: “The scientific community has developed and approved new antibiotics in recent years. This is good, but unfortunately not sufficient to catch up with evolving drug-resistance bacteria, especially against those of greatest concern.</p>
<div class="lb-trans"><p>WHO 抗微生物耐药性主任 Yvan Hutin 博士表示：“科学界近年来开发并批准了新的抗生素。这是好事，但不幸的是，无法赶上不断演变的耐药细菌，尤其是那些最令人担忧的细菌。”</p>
</div><p>“We need a reliable pipeline with new antibacterial agents that are innovative, affordable and accessible to all those who need them.”</p>
<div class="lb-trans"><p>“我们需要一个可靠的管道，提供创新、可负担且所有需要的人都能获得的新抗菌剂。”</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预测？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>来自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><h2>AMR’s health burden</h2>
<div class="lb-trans"><h2>抗微生物耐药性（AMR）的健康负担</h2>
</div><p>Antimicrobial Resistance (AMR) occurs when bacteria, viruses, fungi, and parasites evolve to withstand antimicrobial medicines. In the case of resistant bacteria, antibiotics can be rendered ineffective. In 2023, approximately one in six laboratory-confirmed bacterial infections worldwide were caused by bacteria resistant to antibiotics. It is estimated that bacterial antimicrobial resistance (AMR) was directly responsible for 1.27 million global deaths in 2019, the last year data of this kind is available. It is forecast that AMR will cause ten million deaths by 2050 unless action, such as developing more advanced antibiotics, is taken.</p>
<div class="lb-trans"><p>抗微生物耐药性（AMR）是指细菌、病毒、真菌和寄生虫进化以抵抗抗微生物药物。在耐药细菌的情况下，抗生素可能失效。2023 年，全球约六分之一的实验室确认的细菌感染是由耐药细菌引起的。估计 2019 年，细菌抗微生物耐药性（AMR）直接导致了 127 万人死亡，这是最后一年有此类数据可用的年份。预计如果不采取行动，例如开发更先进的抗生素，到 2050 年 AMR 将导致 1000 万人死亡。</p>
</div><p>In October 2025, the WHO asked its member states, donors and partners to strengthen a coordinated response against AMR. At the time, the health authority was asking for $85m every two years to help fight the public health issue. It is unclear how the US’s departure from WHO will affect AMR specifically, but experts generally believe that global health efforts at the agency will be hampered. The US has historically been the WHO’s largest donor.</p>
<div class="lb-trans"><p>2025 年 10 月，WHO 要求其成员国、捐助者和合作伙伴加强对抗 AMR 的协调响应。当时，卫生机构要求每两年提供 8500 万美元以帮助应对这一公共卫生问题。目前尚不清楚 美国退出 WHO 将如何具体影响 AMR，但专家普遍认为，该机构的全球健康努力将受到阻碍。美国历来是 WHO 最大的捐助国。</p>
</div><p>Other regions have established their own campaigns. The UK, for example, pledged £210m ($267.7m) to help track antibiotic-resistant bacteria across Asia and Africa. The investment, which supports The Fleming Fund’s global antimicrobial resistance surveillance (AMR) programme, aims to identify dangerous superbugs before they arrive in the UK. In September 2025, the European Union launched a €253m initiative to combat AMR.</p>
<div class="lb-trans"><p>其他地区已建立自己的运动。例如，英国 承诺 210 百万英镑（约 267.7 百万美元） 以帮助追踪亚洲和非洲的抗生素耐药细菌。这项投资支持弗莱明基金的全球抗微生物耐药性监测（AMR）计划，旨在在危险超级细菌到达英国之前识别它们。2025 年 9 月，欧盟启动了一项 2.53 亿欧元的倡议，以应对 AMR。</p>
</div>

世界卫生组织将抗生素的开发重点放在优先病原体上